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Abstract
Background: More than 50 mutations in the UBE3A gene (E6-AP ubiquitin protein ligase gene) have been found in
Angelman syndrome patients with no deletion, no uniparental disomy, and no imprinting defect.
Case Presentation: We here describe a novel UBE3A frameshift mutation in two siblings who have inherited it
from their asymptomatic mother. Despite carrying the same UBE3A mutation, the proband shows a more severe
phenotype whereas his sister shows a milder phenotype presenting the typical AS features.
Conclusions: We hypothesized that the mutation Leu125Stop causes both severe and milder phenotypes. Potential
mechanisms include: i) maybe the proband has an additional problem (genetic or environmental) besides the
UBE3A mutation; ii) since the two siblings have different fathers, the UBE3A mutation is interacting with a different
genetic variant in the proband that, by itself, does not cause problems but in combination with the UBE3A
mutation causes the severe phenotype; iii) this UBE3A mutation alone can cause either typical AS or the severe
clinical picture seen in the proband.
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Background
Angelman syndrome (AS) is a neuro-genetic disorder
characterized by intellectual and developmental delay,
sleep disturbance, seizures, jerky movements, frequent
laughter or smiling and a happy disposition [1]. The
incidence of AS is estimated to be between 1/10,000 and
1/20,000 [2] and is inherited in an autosomic dominant
trait, modified by imprinting, or inherited by imprinting
[3]. Analysis of parent-specific DNA methylation pattern in
the 15q11-13 chromosome region detects approximately
77% of individuals with AS, including those cases with a
deletion (approximately 70%), uniparental disomy (1-2%),
or an imprinting defect (3-5%); fewer than 1% of individuals
have a cytogenetically chromosome rearrangement and
UBE3A sequencing detects mutations in approximately 5-
10% of the patients [4]. In 10-15% of the cases the molecu-
lar exam is normal with no deletions, uniparental disomy,
imprinting defects or UBE3A mutations [5]. Recently, it
was demonstrated that the Angelman syndrome protein
Ube3A is a neuronal activity-regulated protein that controls
synaptic function by ubiquitinating and degrading the syn-
aptic protein Arc. In the absence of Ube3A, elevated levels
of Arc accumulate in neurons resulting in the excessive in-
ternalization of AMPA receptors at synapses and impaired
synaptic function [6]. We report a brother and sister who
was referred to our laboratory in order to investigate a cli-
nical suspicion of AS. As the analysis of the differential
parental specific DNA methylation within the 15q11-13
region was normal, we investigated the UBE3A gene in
order to screen for mutations causing AS. We here de-
scribe a novel UBE3A frameshift mutation in two siblings
who have inherited it from their asymptomatic mother.
Despite carrying the same UBE3A mutation, the proband
shows a more severe phenotype whereas his sister shows
the typical AS features associated to a milder phenotype.
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Case presentation
Case report
Patient 1, the proband, aged 14 years and 8 months, was
born from non-consanguineous and healthy parents
(Figure 1A). After a normal pregnancy, the patient was
born at term by cesarean section, weighing 2,900 g
(25th-50th centile), length and head circumference were
not informed. His developmental progress was delayed; he
sat at 1 year old, he is not able to walk. At the age of 9
months, he began to have seizures and has been on val-
proic acid with good control. Unlike typical AS patients,
he did not display a happy disposition with frequent
smiling and laughing. He has normal EEG and brain MRI
shows reduction of the volume of the inferior cerebellar
vermis, increase of the cisterna magna, diffuse atrophy
with decreased volume more pronounced in the fronto-
temporal region, ventriculomegaly, thin corpus callosum.
When he was examined at the age of 11 years old, his head
circumference was 47 cm (<3th centile), height and weight
were not informed. He presented with normal cytogenetic
analysis and normal study of the methylation within the
15q11-13 region.
Patient 2, the proband’s sister, aged 6 years and 3
months, was born from non-consanguineous and healthy
parents (Figure 1B); these two siblings have different
fathers (Figure 2). The prenatal period was uneventful and
the baby was delivered by cesarean section at full term
with a birth weight of 3385 g (50th-75th centile), height of
50 cm (50th-75th centile), and head circumference of 35
cm (75th-90th centile). Her developmental progress was
delayed. She presented hypotonia by age of 7 months, sat
at 2 years old, walked at 3 years old. At the age of 3 years
old, she began to have seizures and has been on fenobarbi-
tal with good control. She has the typical AS phenotype,
happy behavior, wide mouth with wide-spaced teeth,
uplifted flexed arm position, ataxic gait, and excessive
devotion for playing with water. When she was examined
at the age of 4 years old, her head circumference was 47.5
cm (<3th centile), height 110 cm (97th centile), and weight
20.000g (95th centile). She presented the typical EEG for
AS patients, normal brain MRI, normal cytogenetic analysis
and study of the methylation within the 15q11-13 region.
Methods
DNA extraction
The genomic DNA was extracted from leukocytes from
peripheral blood samples, using Super Quick-gene-rapid
DNA isolation (Promega), following the manufacturer’s
instructions.
Methylation analysis using Methylation Sensitive High
Resolution Melting (MS-HRM) assay
For methylation analysis of the SNRPN gene, DNA con-
version using bisulfite and cleanup of 2 μg of genomic
DNA was carried out using EpiTect Bisulfite Kit (Qiagen),
following the manufacturer’s instructions. Afterwards the
DNA conversion, each sample was run in duplicate by the
MS-HRM assay to determine the methylation pattern
within the 15q11-13 region using primers and protocol
described by White et al. (2007) [7]. The MS-HRM ana-
lysis was performed in a 7500 Fast Real-Time PCR System
(Applied Biosystems) using MeltDoctor HRM Master Mix
(Applied Biosystems) according manufacturer’s instruc-
tions. The PCR reaction conditions were 95°C for 10
minutes, followed by 40 cycles of 95°C for 15 seconds, 58°C
for 1 minute and 95°C for 1 minute, followed by the stand-
ard melting curve.
PCR and mutation screening using High Resolution Melting
(HRM) assay
In order to screen for UBE3A mutations, we used the pri-
mers described by Malzac et al. (1998) [8] and the HRM
technique. The HRM analysis was performed in a 7500
Fast Real-Time PCR System (Applied Biosystems) using
MeltDoctor HRM Master Mix (Applied Biosystems)
according manufacturer’s instructions. Each sample was
run in duplicate and approximately 20 ng of genomic DNA
was amplified in a total volume of 20 μl containing 5 μM of
Figure 1 Patients here reported. In A) we observe the proband clinical features; In B) we observe the proband’s sister clinical features.
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each primer, deionizated water, and 10μl of MeltDoctor.
master mix (Applied Biosystems). The PCR reaction con-
ditions were 95°C for 10 minutes, followed by 40 cycles of
95°C for 15 seconds, 55°C for 1 minute and 95°C for
1 minute, followed by the standard melting curve.
Cloning and DNA sequencing
DNA fragments amplified by PCR were subjected to direct
sequencing in an automatic capillary sequencing system
ABI 3130 Genetic Analyser using BigDyeR Terminator
v3.1 Cycle Sequencing kit, following the manufacturer’s
instructions. The sequencing results were analyzed
through FinchTV version 1.4.0 (Geospiza Inc. 2004–2006);
the sequences obtained were compared with reference
from the GenBank (NM_130.839.1). In order to proper
characterize the mutation, the same DNA fragments
amplified by PCR were cloned into TOPOR vector using
TOPO TA cloning (Invitrogen) according to manufac-
turer’s instructions.
Conclusions
Kubota et al., (1997) [9] have developed a methylation-
specific PCR assay for detection of the PWS and AS based
on the methylation status of the CpG island within the
SNRPN gene. More recently a similar protocol was devel-
oped based on comparing melting profiles of experimental
samples to melting profiles from DNA with known methy-
lation levels. This assay is called Methylation Sensitive
HRM (MS-HRM) [10] and is also employed to analyze the
differential methylation at the SNRPN locus [7]. Carrying
on our methylation experiments by using the MS-HRM
protocol, analysis of samples from the two siblings with
AS phenotype and their asymptomatic mother (Figure 2)
revealed a normal methylation pattern (Figure 3A), ex-
cluding the possibility of deletion, uniparental disomy or
imprinting mutation encompassing the SNRPN locus. In
order to characterize the molecular defect, the entire cod-
ing region of UBE3A gene was screened for mutations
using the HRM method. The result revealed that exon 9
of both siblings and their mother share an abnormal pat-
tern of melt curve when compared with the control
(Figure 3B). Afterwards, the DNA sequencing of exon 9
showed a deletion of four nucleotides (TAAC) affecting
codons 125 and 126 resulting in a frameshift mutation,
which creates a premature stop codon at position 125,
1031-1034delTAAC (Leu125Stop) (Figure 4). In this sce-
nario, we concluded that the mutation was transmitted
from a paternal chromosome inherited from the mother.
The majority of mutations found within UBE3A gene are
localized at the hect domain region, which includes the
3′region of the exon 9, extends through the exon–16.
All of them are frameshift mutations leading to stop
codons [11-15]. The mutation described in the present
study is localized at the begining of exon 9 causing a
frameshift mutation changing the entire hect domain. Hui-
bregtse et al. (1995) [16] have previously reported that a
UBE3A mutant protein lacking the last six amino acids is
completely defective in ubiquitination. Thus, we predict
that the protein product from the mutated UBE3A
reported here will also be completely defective in ubiquiti-
nation. We report here that in spite of carrying the same
mutation, the proband shows a more severe phenotype as
he is not able to walk and does not present some of the
typical AS facial features as wide mouth with wide-spaced
teeth, happy behavior, arm positions and movements.
Also, he presents abnormal MRI showing severe abnor-
malities which are not the typical MRI findings for AS.
On the other hand, his sister presents a milder phenotype,
compared to her brother, including the typical AS features
as wide mouth and spaced teeth, ataxic gait, arm
movements, happy behavior, attraction to water. It has
already been reported that UBE3A mutations resulting in
Figure 2 Histogram representing the pedigree evaluated in the case reported. Black square: proband (patient 1 – III.1); Black circle:
proband’s sister (patient 2 – III.5).
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frameshifts and/or premature truncations give a more
severe phenotype than missense mutations or short in-
frame deletions that still allow the translation of a full-
length protein [4]. Baumer et al. (1999) [14] have reported
that patients with UBE3A mutations and deletions present
a more severe phenotype as the patient shows all the
clinical features and, the milder phenotype is reported
among patients carrying paternal uniparental disomy and
imprinting defect. Also, Malzac et al. (1998) [8] reported
that the phenotype due to UBE3A mutation did not differ
regardless of the mutation and they also reported that the
clinical phenotype presented by the patient carrying a
UBE3A mutation is the typical AS phenotype. However,
some patients carrying UBE3A mutations showed milder
phenotype, as they do not present ataxic gait, seizures,
microcephaly, and normal EEG [13,15]. We hypothesized
Figure 3 High resolution melthing analysis. For both MS-HRM and HRM for screening for mutations, each sample was run in duplicate. In A)
the melting curves observed for the PCR fragment analyzed in methylation-specific HRM (MS-HRM) assay for the SNRPN locus are shown. Blue
lines represent the pattern of methylation of SNRPN for patients affected by Prader-Willi Syndrome (PWS); Red lines represent the pattern of
methylation of SNRPN for patients affected by Angelman Syndrome (AS); Green lines represent the normal pattern of methylation of SNRPN locus:
1 shows the methylation curve detected in the normal control and mother (II.1); 2 shows the methylation curve detected in patient III.1 and 3
shows the methylation curve detected in patient III.5. In B) the melting curves observed for the PCR fragment analyzed in HRM assay for the
screening of mutations in the UBE3A gene are shown. Blue lines represent the melting curve pattern obtained for healthy controls presenting
with a normal UBE3A gene (without any mutation); Green lines represent the melting curve pattern obtained for all individuals (II.1, III.1 and III.5)
presenting with the 1031-1034delTAAC mutation in the UBE3A gene.
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that the mutation Leu125Stop causes both severe and
milder phenotypes. We reported a similar observation
where a duplication of GAGG at exon 10 of UBE3A caused
different phenotypes in first cousins [17]. Perhaps similar
mechanisms explain the phenotypic differences between
the related patients. Potential mechanisms include: i)
maybe the proband has an additional problem (genetic or
environmental) besides the UBE3A mutation; ii) since the
two siblings have different fathers, the UBE3A mutation is
interacting with a different genetic variant in the proband
that, by itself, does not cause problems but in combination
with the UBE3A mutation causes the severe phenotype; iii)
this UBE3A mutation alone can cause either typical AS or
the severe clinical picture seen in the proband.
In addition, as shown in Figure 3A, we observed three
differential methylation patterns. This result may be asso-
ciated to the phenotypic variability observed between
patients, due to the differential methylation pattern along
the SNRPN analyzed region containing 21 CpG dinucleo-
tides. To test this hypothesis we performed the bisulfite se-
quencing analysis of the patients, their mother and a
normal control (Additional file 1). All the samples showed
the same heterozygous CpG methylation pattern as
expected in cases of AS patients with biparental inheritance
(Additional file 1). We also observed that all cytosine in
CpG dinucleotides were heterozygous (T/C) with a small T
peak height compared to the C peak height. The bisulfite
conversion was efficient since all the isolated cytosine was
fully converted into thymine. No mutation was observed in
the same region. The imbalance observed between the
methylated allele (observed as the C peak in the chromato-
gram) and the non-methylated allele (observed as the T
peak in the chromatogram) is due to the peripheral blood
cell heterogeneity where CpG methylation status is differ-
entially maintained in the PWS/AS region [18,19].
It is worthy to discuss that this is the first paper using
HRM to search for mutations within the UBE3A gene.
HRM is a relatively new technique, which is being widely
used as a method for screening for mutations [20]. There-
fore, it provides very simple solutions for genotyping as
this technique combines high sensitivity and specificity
making it useful for personalized DNA diagnostics.
Consents
Written informed consent was obtained from the patient’s
mother for publication of this Case Report and any
accompanying images. A copy of the written consent is
available for review by the Series Editor of this journal.
Figure 4 DNA sequencing of UBE3A gene for patients III.1 and III.5. A) Schematic representation of the structure of UBE3A gene. Squares:
exons; White squares: untranslated regions (UTRs); Black squares: coding exons; Black line: introns. B) The upper panel shows the direct
sequencing of the DNA fragment obtained subsequently to PCR. Middle and lower panels show the sequencing of the same DNA fragments
amplified by PCR after cloning into TOPO TA cloning vector (Invitrogen). The middle panel shows the sequencing obtained for the mutated allele
[1031-1034delTAAC (Leu125Stop)], and the lower panel shows the sequencing obtained for the non-mutated allele.
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Additional file
Additional file 1: DNA sequencing after bisulfite conversion.
A) Shows part of the SNRPN region analyzed in this work. 1. SNRPN
sequence before bisulfite conversion; in bold we show the CpG
dinucleotides. 2. SNRPN sequence after bisulfite conversion; in red we
show the isolated cytosine which were converted into thymine. B) The
sequencing obtained for the mother (II.5), patient III.1 and patient III.5
after the bisulfite conversion. * shows the CpG dinucleotides.
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